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Outline
- Review coronavirus life-cycle
- Review mechanism of action of remdesivir 
- Review previous research on remdesivir
- Wang et al
- Beigel et al
- Close reading of article
- Methods
- Results
- Discussion
- Future research
- Implications for our practice
- Targets respiratory and GI tract 
- Interaction of spike protein and 
ACE-2 receptor
- Genome translation
- Protein cleavage
- Translation and RNA replication 
(RdRp)
- Packaging and virion release
Viral Life-cycle 
Mechanism of 
action
- Prodrug - nucleoside 
analogue (adenosine)
- RNA chain 
incorporation 
- Delayed chain 
termination
- Both in vitro and in vivo 
antiviral activity
- SARS, Ebola virus, 
MERS
Background research
- April 29, 2020 in Lancet
- First multicenter, randomized, double-blind, placebo-controlled 
superiority trial of remdesivir in COVID
- Population: 237 adults hospitalized with RT-PCR-confirmed SARS COV2 
at 10 hospitals in Wuhan, China were included; 158 received RDV, 79 
received placebo
- Intervention: RDV 200 mg IV on day 1 + 100 mg IV daily x9 days (10 days 
total) + usual care
- Control: Placebo (10 days total) + usual care
Wang et al
- The study was stopped early due to poor recruitment after including 
237 patients
- The primary endpoint was time to clinical improvement. 
- There was no statistically significant difference in this endpoint, but 
possible small reduction in time (21 vs. 23 days). 
- Lack of an observable effect could be caused by:
- Delayed administration (median duration of illness prior to 
administration = 10 days) 
- Underpowering 
Background research
- May 22, 2020 in NEJM
- Randomized, double-blind,  
placebo controlled trial testing 
efficacy of IV remdesivir for 
hospitalized adults with COVID-19.  
- 1063 patients were randomized
- Treatment arm: 10 days IV 
remdesivir (Day 1: 200mg, followed 
by 9 days 100mg) 
- Patients with renal failure excluded 
and no GFR cutoff given!
- Primary endpoint switched 
mid-trial from clinical improvement 
to time to recovery
Beigel et al
- Primary outcome: time to clinical recovery
- Remdesivir group recovered in 11 days compared to 15 days in the 
control group
- Improvement was greatest in a subgroup analysis of less ill 
patients 
- No benefit among patients on high-flow oxygen, noninvasive 
ventilation, or invasive ventilation
- Among secondary endpoints:
- No mortality benefit
- EMCrit.org: Reduction in hospitalization duration versus increased 
admission of borderline patients to receive IV therapy
Summary of background research
Wang et al suggests that remdesivir accelerates recovery by 2 days on average. Beigel et 
al suggests 4 days to recovery.
It remains unclear whether remdesivir might affect long-term outcomes 
Patients with renal failure were excluded from ACTT-1 trial
Implications for how healthcare system interacts with these patients (perceived 
availability of a therapy could increase those who seek tests...admissions for IV 
remdesivir?)
Journal club article 
Study question
Does treatment with intravenous 
remdesivir for 10 days compared to 
5 days in patients hospitalized with 
coronavirus disease 2019 
(COVID-19) improve clinical status 
at day 14 of hospitalization?
Methods
- Randomized
- Open-label
- Phase 3 trial 
- N=397 patients (200 in 5 day, 197 in 10 day)
- 55 hospitals in the United States, Italy, Spain, Germany, Hong Kong, Singapore, 
South Korea, and Taiwan 
- March 6 - March 26, 2020
- 200 mg of remdesivir on day 1, followed by 100 mg of remdesivir once daily for the 
subsequent 4 or 9 days. 
- Both treatment groups continued supportive therapy at the discretion of the 
investigator throughout the duration of the trial
Inclusion and exclusion criteria
Inclusion criteria
● Oxygen saturation 94% or lower on room air
● Radiologic evidence of pneumonia
● PCR assay within four days of randomization
● Age >11 years old
● Women included only if not pregnant
Exclusion criteria
● Intubation at screening
● ECMO at screening 
● Patients with signs of multiorgan failure
● (ALT) or aspartate aminotransferase (AST) levels greater than 5 times the ULN
● Estimated creatinine clearance of less than 50 ml/min
● Patients receiving concurrent treatment (within 24 hours before the start of trial treatment) with 
other agents with putative activity against Covid-19 were excluded.
Patient Characteristics
10-day group was sicker: 
- 13 patients developed need for 
ECMO or MV between screening 
and treatment
- 4 of these patients (2%) were 
assigned to a 5-day course of 
remdesivir and 9 (5%) to a 10-day 
course.
- High-flow oxygen support was 
required at baseline by more 
patients in the 10-day group than 
in the 5-day group (30% vs. 24%)
- Difference was statistically 
significant (P = 0.02).
Primary endpoint
Original primary endpoint of the study was normalization of temperature and oxygen 
saturation through day 14. 
 
This was changed to assessment of clinical status using a 7-point ordinal scale on March 
15, with clinical status values collected from day 1 to 14, or until discharge. 
1) death
2) hospitalized, receiving invasive mechanical ventilation or ECMO
3) hospitalized, receiving noninvasive ventilation or high-flow oxygen devices
4) hospitalized, requiring low-flow supplemental oxygen
5) hospitalized, not requiring supplemental oxygen but receiving ongoing medical 
care (related or not related to Covid-19)
6) hospitalized, requiring neither supplemental oxygen nor ongoing medical care 
(other than that specified in the protocol for remdesivir administration
7) not hospitalized
Secondary and exploratory endpoints
Secondary 
Proportion of patients with adverse events that occurred on or after the first dose of 
remdesivir for up to 30 days after the last dose.
Exploratory
- Time to clinical improvement (defined as an improvement of at least 2 points from 
baseline on the 7-point ordinal scale)
- Time to recovery (defined by the National Institute of Allergy and Infectious 
Diseases [NIAID] as an improvement from a baseline score of 2 to 5 to a score of 6 
or 7)
- Time to modified recovery (defined as an improvement from a baseline score of 2 
to 4 to a score of 5 to 7 or from a score of 5 to a score of 6 or 7)
- Death from any cause.
By day 14, clinical improvement of 2 
points or more on the ordinal scale:
- 64% of patients in the 5-day 
group
- 54% in the 10-day group. 
After adjustment for baseline clinical 
status, 10-day group had distribution 
in clinical status at day 14 that was 
similar to that among patients in the 
5-day group (P=0.14).
Results: 
Clinical 
improvement
Time to recovery
The median time to recovery: 
- 10 days among patients in 
the 5-day group 
- 11 days among patients in 
the 10-day group. 
Time to modified recovery: 
- 9 days among patients in 
the 5-day group 
- 10 days among patients in 
the 10-day group. 
Results: 
Length of stay,
mortality
Median duration of hospitalization among patients 
discharged on or before day 14 was slightly shorter for 5 
day group
More patients were discharged from the hospital in the 
5-day group than in the 10-day group
Mortality was numerically lower in 5 day group
Discharge rates higher among patients who had had 
symptoms for less than 10 days before receiving the first 
dose of remdesivir (62%) than among those who had had 
symptoms for 10 or more days before receiving the first 
dose (49%).
Measures 5 day tx 10 day tx
Duration of 
hospitalization
7 days 8 days
Percent 
discharged
60% 52%
Mortality 8% 11%
Posthoc 
analysis
 Purpose:  determine whether any subpopulation might have benefitted from receiving more 
than 5 days of therapy 
Of patients on invasive mechanical ventilation, those treated with 10 days of remdesivir had 
lower mortality (7/41 vs. 10/25, p=0.048)
However: these subgroups were generated based on clinical status on day #5 – five days after 
patients had started therapy
Safety
Adverse events: 
- 70% in 5 day group
- 74% in 10 day group
Serious adverse events:  
- 21% in 5 day group
- 35% in 10 day group
Percentage of patients who discontinued 
treatment owing to adverse events: 4% 
vs 10% 
https://emcrit.org/pulmcrit/remdesivir-5-10/
p=0.01
p=0.003
Safety
Laboratory abnormalities of grade 
3: 27% vs 34% 
Most abnormalities were transient, 
with no significant difference 
between the median changes in 
the two groups at day 14. 
Grade 4 creatinine clearance 
reductions: 
- 3% vs 12% 
- 71% of these pts: MV, NIPPV, 
HFNC at baseline
https://emcrit.org/pulmcrit/remdesivir-5-10/
p ﹤0.001
Conclusions
In patients with severe Covid-19 without 
mechanical ventilation requirement:
- No significant difference between a 
5-day course and a 10-day course of 
remdesivir 
- Specifically in disease severity, time 
to recovery, length of stay
There are significant nephrotoxic events 
noted in 10 day group
Discussion
The 10-day group included a significantly higher percentage of patients in the most severe disease 
categories
-  Those requiring invasive mechanical ventilation and high-flow oxygen
-  Higher proportion of men (68%, vs. 60%), who are known to have worse outcomes with 
Covid-19
“ Though results suggest that longer treatment with remdesivir may be detrimental, the trend 
toward improved outcomes in the 5-day group was already evident at day 5 of the trial — when 
both groups had received the same amount of treatment — which suggests that differences 
between the groups were not due to treatment duration but to observed imbalances in baseline 
characteristics between the two groups.”
Prior RCTs on remdesivir in COVID-19 have not reported increased rates of renal failure
Limitations
- Funded, designed, monitored and written by Gilead
- Lack of placebo controlled group
- Open label
- Size
- Demographics
- Exclusion criteria (renal function)
- Baseline differences between 5 and 10 day groups
Future research directions
- Study of patients who require mechanical ventilation- might this group benefit 
from 10 days of remdesivir treatment
- Specific trials of high risk groups, such as immunocompromised persons
- Further placebo-controlled trials 
Summary & 
Practice implications
- No placebo control => not a test of the 
efficacy of remdesivir
- If used, remdesivir use should be limited 
to 5 days
- Supplies that are likely to be limited can 
be conserved with shorter durations of 
therapy
- Potentially shorter hospital stays
- Currently not studied in patients with 
impaired renal function
Thanks!
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